# Asarfi Hospital (NSE: ASARFI) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/ASARFI · Pivot · prices to 19 Oct 2026

With a market capitalisation of ₹446 Cr, it ranks 1853rd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Medical Care Facilities.

Its return on equity was 17.1% in FY26. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹45 Cr (+33.5% year on year) and net profit ₹4 Cr (+9.2%), on a consolidated basis. Promoters held 61.17% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Market cap | ₹446 Cr |
| ROE | 17.1% (FY26) |
| ROCE | 18.4% (FY26) |
| Debt to equity | 0.59 |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹45 Cr | +33.5% | ₹4 Cr | +9.2% | ₹1.99 |
| Q3 FY26 | ₹46 Cr | +40.2% | ₹5 Cr | +102.2% | ₹2.76 |
| Q2 FY26 | ₹45 Cr | +45.5% | ₹4 Cr | +47.4% | ₹2.13 |
| Q1 FY26 | ₹36 Cr | +55.7% | ₹3 Cr | +115.2% | ₹1.59 |
| Q4 FY25 | ₹34 Cr | +41.0% | ₹4 Cr | — | ₹1.82 |
| Q3 FY25 | ₹33 Cr | +64.0% | ₹3 Cr | — | ₹1.36 |
| Q2 FY25 | ₹31 Cr | — | ₹3 Cr | — | ₹1.45 |
| Q1 FY25 | ₹23 Cr | — | ₹1 Cr | — | ₹0.74 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹121 Cr | ₹11 Cr |
| FY24 | ₹84 Cr | ₹4 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 61.17%
- Domestic institutions: 2.97%
- Non-institutions: 35.86%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Prevest Denpro](https://app.pivotnow.in/stock/PREVEST) | — | ₹472 Cr | — | — |
| [HALEOS LABS](https://app.pivotnow.in/stock/HALEOSLABS) | ₹1,540.00 | ₹466 Cr | 26.9 | — |
| [Albert David](https://app.pivotnow.in/stock/ALBERTDAVD) | ₹795.00 | ₹454 Cr | — | — |
| [Jenburkt Pharma](https://app.pivotnow.in/stock/JENBURPH) | ₹905.20 | ₹399 Cr | 11.5 | — |
| [Transchem](https://app.pivotnow.in/stock/TRANSCHEM) | — | ₹391 Cr | — | — |
| [Aptus Pharma](https://app.pivotnow.in/stock/APPL) | — | ₹377 Cr | — | — |

## Questions and answers

### What is the market cap of Asarfi Hospital?

Asarfi Hospital's market capitalisation is ₹446 Cr (₹446 Cr) at the 19 Oct 2026 close, ranking 1853rd among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Asarfi Hospital?

Return on equity was 17.1% in FY26 and return on capital employed was 18.4% in FY26 (consolidated figures).

### Is Asarfi Hospital a debt-free company?

No. Asarfi Hospital's debt-to-equity ratio was 0.59 in FY26, with total debt of ₹35 Cr.

### What were Asarfi Hospital's latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Asarfi Hospital reported revenue of ₹45 Cr, +33.5% year on year, and net profit of ₹4 Cr, +9.2% year on year.

### What is the shareholding pattern of Asarfi Hospital?

As of 30 Jun 2026: promoters 61.17%, domestic institutions 2.97%, non-institutions 35.86%.

### Who are Asarfi Hospital's competitors?

The listed Pharma & Healthcare companies closest to Asarfi Hospital by market cap are Prevest Denpro, HALEOS LABS, Albert David, Jenburkt Pharma, Transchem and Aptus Pharma.

### Is Asarfi Hospital a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Asarfi Hospital's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on ASARFI against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.